Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GMABNASDAQ:ITCINASDAQ:PCVXNYSE:RDY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGMABGenmab A/S$21.15+1.7%$20.39$17.24▼$30.41$13.56B1.071.06 million shs1.35 million shsITCIIntra-Cellular Therapies$131.87$131.29$64.09▼$131.98$14.05B0.691.47 million shsN/APCVXVaxcyte$35.84+3.1%$52.73$27.66▼$121.06$4.62B1.261.24 million shs1.58 million shsRDYDr. Reddy's Laboratories$13.92-0.1%$13.20$12.26▼$16.89$11.62B0.511.47 million shs1.25 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGMABGenmab A/S+0.78%+2.57%+4.47%+4.74%-27.23%ITCIIntra-Cellular Therapies0.00%0.00%+0.05%+3.82%+82.39%PCVXVaxcyte+5.68%+11.23%-49.94%-60.79%-43.03%RDYDr. Reddy's Laboratories-0.07%+0.61%+5.65%+2.90%-6.35%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGMABGenmab A/S4.4327 of 5 stars4.35.00.00.03.40.03.1ITCIIntra-Cellular Therapies0.8805 of 5 stars1.10.00.04.51.11.70.6PCVXVaxcyte3.0068 of 5 stars4.61.00.00.03.52.50.0RDYDr. Reddy's Laboratories1.852 of 5 stars2.32.01.70.03.40.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGMABGenmab A/S 2.69Moderate Buy$39.1785.19% UpsideITCIIntra-Cellular Therapies 2.17Hold$109.70-16.81% DownsidePCVXVaxcyte 3.10Buy$136.50280.86% UpsideRDYDr. Reddy's Laboratories 2.50Moderate Buy$17.0022.13% UpsideCurrent Analyst Ratings BreakdownLatest PCVX, ITCI, GMAB, and RDY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/22/2025PCVXVaxcyteCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight4/9/2025GMABGenmab A/SHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.00 ➝ $37.004/8/2025PCVXVaxcyteNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$90.00 ➝ $90.004/2/2025ITCIIntra-Cellular TherapiesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$132.00 ➝ $132.004/1/2025GMABGenmab A/SSanford C. BernsteinSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeMarket Perform ➝ Underperform4/1/2025PCVXVaxcyteThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$138.00 ➝ $100.004/1/2025PCVXVaxcyteBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$157.00 ➝ $137.004/1/2025PCVXVaxcyteNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$140.00 ➝ $90.003/31/2025PCVXVaxcyteEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/12/2025PCVXVaxcyteGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$160.00 ➝ $160.003/11/2025GMABGenmab A/STruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$50.00 ➝ $45.00(Data available from 4/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGMABGenmab A/S$21.53B0.63$1.43 per share14.80$8.04 per share2.63ITCIIntra-Cellular Therapies$680.50M20.64N/AN/A$6.15 per share21.44PCVXVaxcyteN/AN/AN/AN/A$13.04 per shareN/ARDYDr. Reddy's Laboratories$311.31B0.04$1.05 per share13.25$4.50 per share3.09Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGMABGenmab A/S$1.14B$1.7412.1611.882.6536.30%16.78%13.79%5/8/2025 (Estimated)ITCIIntra-Cellular Therapies-$139.67M-$0.73N/A694.05N/A-14.07%-9.93%-8.38%5/6/2025 (Estimated)PCVXVaxcyte-$402.27M-$3.80N/AN/AN/AN/A-23.53%-22.20%5/6/2025 (Estimated)RDYDr. Reddy's Laboratories$668M$0.6322.1716.98N/A17.25%17.87%12.32%5/6/2025 (Estimated)Latest PCVX, ITCI, GMAB, and RDY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025PCVXVaxcyte-$1.02N/AN/AN/AN/AN/A5/8/2025Q1 2025GMABGenmab A/S$0.26N/AN/AN/A$5.17 billionN/A5/6/2025Q4 24/25RDYDr. Reddy's Laboratories$0.20N/AN/AN/A$83.70 billionN/A2/25/2025Q4 2024PCVXVaxcyte-$1.16-$1.02+$0.14-$1.02N/AN/A2/21/2025Q4 2024ITCIIntra-Cellular Therapies-$0.08-$0.16-$0.08-$0.16$205.08 million$199.22 million2/12/2025Q4 2024GMABGenmab A/S$0.28$0.57+$0.29$0.85$884.02 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGMABGenmab A/SN/AN/AN/AN/AN/AITCIIntra-Cellular TherapiesN/AN/AN/AN/AN/APCVXVaxcyteN/AN/AN/AN/AN/ARDYDr. Reddy's Laboratories$0.080.57%N/A12.70%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGMABGenmab A/SN/A5.255.24ITCIIntra-Cellular TherapiesN/A7.667.51PCVXVaxcyteN/A17.8817.88RDYDr. Reddy's Laboratories0.021.921.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGMABGenmab A/S7.07%ITCIIntra-Cellular Therapies92.33%PCVXVaxcyte96.78%RDYDr. Reddy's Laboratories3.85%Insider OwnershipCompanyInsider OwnershipGMABGenmab A/S1.54%ITCIIntra-Cellular Therapies2.60%PCVXVaxcyte3.10%RDYDr. Reddy's Laboratories2.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGMABGenmab A/S1,660641.20 million651.58 millionOptionableITCIIntra-Cellular Therapies560106.52 million103.56 millionOptionablePCVXVaxcyte160128.94 million120.77 millionOptionableRDYDr. Reddy's Laboratories24,800834.77 million818.05 millionOptionablePCVX, ITCI, GMAB, and RDY HeadlinesRecent News About These CompaniesInvesco Ltd. Grows Stock Position in Dr. Reddy's Laboratories Limited (NYSE:RDY)April 29 at 3:41 AM | marketbeat.comDr. Reddy's Laboratories advances Monday, underperforms competitorsApril 28 at 6:41 AM | marketwatch.comJump Financial LLC Increases Stock Position in Dr. Reddy's Laboratories Limited (NYSE:RDY)April 28 at 4:10 AM | marketbeat.comEnvestnet Asset Management Inc. Has $2.61 Million Holdings in Dr. Reddy's Laboratories Limited (NYSE:RDY)April 28 at 3:25 AM | marketbeat.comLegal & General Group Plc Has $2.31 Million Stock Holdings in Dr. Reddy's Laboratories Limited (NYSE:RDY)April 27 at 3:45 AM | marketbeat.comDr. Reddy's Laboratories Limited (NYSE:RDY) Shares Acquired by Mariner LLCApril 26, 2025 | marketbeat.comDr. Reddy's Laboratories slides Friday, outperforms competitorsApril 25, 2025 | marketwatch.comBI Asset Management Fondsmaeglerselskab A S Has $1.33 Million Stake in Dr. Reddy's Laboratories Limited (NYSE:RDY)April 25, 2025 | marketbeat.comDr. Reddy's Laboratories slides Tuesday, underperforms competitorsApril 22, 2025 | marketwatch.comGuggenheim Capital LLC Raises Position in Dr. Reddy's Laboratories Limited (NYSE:RDY)April 22, 2025 | marketbeat.comGeode Capital Management LLC Buys 1,163,575 Shares of Dr. Reddy's Laboratories Limited (NYSE:RDY)April 21, 2025 | marketbeat.comRussell Investments Group Ltd. Increases Stock Position in Dr. Reddy's Laboratories Limited (NYSE:RDY)April 20, 2025 | marketbeat.comDr. Reddy's Laboratories Limited (NYSE:RDY) Shares Purchased by Cerity Partners LLCApril 19, 2025 | marketbeat.comLPL Financial LLC Increases Stock Position in Dr. Reddy's Laboratories Limited (NYSE:RDY)April 17, 2025 | marketbeat.comDr. Reddy's Laboratories Limited (NYSE:RDY) Shares Purchased by Promethos Capital LLCApril 16, 2025 | marketbeat.comCauseway Capital Management LLC Grows Position in Dr. Reddy's Laboratories Limited (NYSE:RDY)April 16, 2025 | marketbeat.comZacks Industry Outlook Dr. Reddy's, Sandoz and Teva PharmaceuticalsApril 16, 2025 | uk.finance.yahoo.comDr. Reddy's Laboratories rises Wednesday, outperforms competitorsApril 16, 2025 | marketwatch.comDr Reddy’s denies reports of cost cut through workforce reductionApril 14, 2025 | seekingalpha.comDr Reddy’s initiates 25% workforce reduction, report suggestsApril 14, 2025 | msn.comDr. Reddy’s Laboratories (RDY): Among the Best Indian Stocks to Buy According to BillionairesApril 14, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePCVX, ITCI, GMAB, and RDY Company DescriptionsGenmab A/S NASDAQ:GMAB$21.15 +0.36 (+1.73%) As of 04:00 PM EasternGenmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.Intra-Cellular Therapies NASDAQ:ITCI$131.87 0.00 (0.00%) As of 04/2/2025Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.Vaxcyte NASDAQ:PCVX$35.84 +1.07 (+3.08%) As of 04:00 PM EasternVaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.Dr. Reddy's Laboratories NYSE:RDY$13.92 -0.02 (-0.14%) As of 03:58 PM EasternDr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hims & Hers Stock Soars on Novo Nordisk Collaboration 3 Dividend Kings Outshining the Market in 2025 Tesla's Band-Aid Has Been Ripped Off: Rally Mode Engaged Amazon's Earnings Will Make or Break the Stock's Comeback Why D-Wave's Project With Davidson Is a Game-Changer For Quantum NXP Semiconductors: A Buy-and-Hold Stock in the Buy Zone Joby Aviation Shares Eye Breakout After Transition Flight Win Altria’s Resilient Strategy Keeps It a Top Dividend Play in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
